louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01456390: Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents
Official title: A Prospective Evaluation of Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Open-Angle Glaucoma
Keywords: Open angle glaucoma
Prior trabeculectomy
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2011-10-20
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evaluation in the eyes of subjects with one prior trabeculectomy on one to three ocular hypotensive medications of the intraocular pressure (IOP) lowering effect of two iStent stents in combination with one iStent supra stent and a postoperative prostaglandin.

Detailed description: Evaluation in the eyes of subjects with one prior trabeculectomy on one to three ocular hypotensive medications of the intraocular pressure (IOP) lowering effect of two iStent stents in combination with one iStent supra stent and a postoperative prostaglandin.

Eligibility criteria: Inclusion Criteria:

* Phakic patients or pseudophakic patients with posterior chamber intraocular lenses (PC-IOLs)
* Open-angle glaucoma (including pseudoexfoliative)

Exclusion Criteria:

* Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs)
* Prior ALT
* Prior SLT within 90 days of screening visit

Primary outcomes:
measure: Subjects observed at Month 12 who experience a mean medicated diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOP
timeFrame: 12 Months
Secondary outcomes:
measure: Mean diurnal IOP < 18mm Hg
timeFrame: 12 months
Other outcomes:
measure: Safety/adverse event monitoring
timeFrame: 0-61 months
Locations:
city: Yerevan
country: Armenia
facility: S.V. Malayan Ophthalmological Center
Study officials:
affiliation: S.V. Malayan Ophthalmological Center, Yerevan, Armenia
name: Lilit A Voskanyan, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Myers JS, Masood I, Hornbeak DM, Belda JI, Auffarth G, Junemann A, Giamporcaro JE, Martinez-de-la-Casa JM, Ahmed IIK, Voskanyan L, Katz LJ. Prospective Evaluation of Two iStent(R) Trabecular Stents, One iStent Supra(R) Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes. Adv Ther. 2018 Mar;35(3):395-407. doi: 10.1007/s12325-018-0666-4. Epub 2018 Feb 23.
Clinical trial NCT04391790: MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy
Official title: Randomized Controlled Trial With a MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy - MOSAIC
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bladder Cancer
Keywords: ureteral strictures
urinary diversion
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2020-05-18
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A prospective, multicenter, randomized clinical trial
Primary purpose: PREVENTION

Brief summary: Cystectomy is the chosen treatment of bladder cancer in 400 cases every year in DK. In replacement of the removed bladder, a urinary diversion is constructed using 15cm of terminal ilium (Ad Modum Bricker).

Ureteral strictures are diagnosed in 15% of the cystectomized patients, and these patients are at increased risk of infections, loss of renal function and repeated interventions. The left ureter is diagnosed with 70% of all strictures, presumably due to the construction of the urinary diversion.

A modified urinary diversion have been tested in two small studies. The modified diversion is prolonged with 5cm compared to the conventional urinary diversion. The prolongation permits the urinary diversion to reach both the left and the right side of the abdomen, resulting in greater resection of non-viably distal ureter and less mobilization of the left ureter, lowering the rates of strictures.


Eligibility criteria: Inclusion Criteria:

* Bladder cancer with the indication for robot assisted radical cystectomy
* Ileal conduit ad modum Bricker as planned urinary diversion
* Ability to understand the participant information orally and in writing
* Signed consent form

Exclusion Criteria:

* Previous abdominal or pelvic radiotherapy
* Previous major abdominal surgery involving resection of bowel or construction of an enteric stoma
* Urostomy planned on the left side of the abdomen
* Single kidney
* Complete ureteral duplication (either uni- or bilaterally), known at time of inclusion
* Pregnancy

Primary outcomes:
measure: Strictures
timeFrame: Within 2 years after cystectomy
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Department of Urology, Aalborg University Hospital
city: Aarhus
country: Denmark
facility: Department of Urology, Aarhus University Hospital
city: Herlev
country: Denmark
facility: Department of Urology, Herlev and Gentofte Hospital
city: København
country: Denmark
facility: Department of Urology, Rigshospitalet
city: Odense
country: Denmark
facility: Department of Urology, Odense University Hospital
Study officials:
References:
Clinical trial NCT00496990: Treating the Partners of Drug Using Pregnant Women: Stage II
Official title: Treating the Partners of Drug Using Pregnant Women: Stage II
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Drug Addiction
Keywords: male
female
couple
cocaine
opiate
methadone
detoxification
pregnancy
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2007-07-06
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a two group randomized design that will compare a novel therapy package (i.e., Research supported treatment intervention, Contingency-based voucher incentives for the male partner's drug abstinence, Specialized MI couples counseling) to standard care for helping drug using partners of drug dependent pregnant women obtain and maintain drug abstinence. Participants will be followed for 22 weeks and have scheduled twice weekly urine sample collection and all participants will have follow-up interviews post-study entry.


Eligibility criteria: Inclusion Criteria:

* are 18 years of age or older on admission;
* Pregnant as determined by sonogram results
* have a current sexual partner who they have seen recently at least 3 times a week
* male partner has regular alcohol or illicit drug use (at least 4 of 7 days typical use) and is not incarcerated.

Exclusion Criteria:

* woman or partner report current suicidal ideation
* woman or partner meet diagnostic criteria for a current DSM-IV Axis I thought disorder (i.e. schizophrenia)
* woman or partner demonstrate significant cognitive impairment that precludes them from completing the initial assessment battery
* woman has evidence of physical violence or abuse

Primary outcomes:
measure: Partner Objective Substance Use
timeFrame: treatment entry until 28 weeks later
Secondary outcomes:
measure: Woman's drug use will be measured with urine toxicology
timeFrame: treatment entry until 28 weeks later
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Center for Addiction and Pregnancy Johns Hopkins Bayview Medical Center
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Hendree Jones, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lund IO, Kirtadze I, Otiashvili D, O'Grady KE, Jones HE. Female partners of opioid-injecting men in the Republic of Georgia: an initial characterization. Subst Abuse Treat Prev Policy. 2012 Nov 16;7:46. doi: 10.1186/1747-597X-7-46.
citation: Kirtadze I, Otiashvili D, O'Grady KE, Jones HE. Behavioral treatment + naltrexone reduces drug use and legal problems in the Republic of Georgia. Am J Drug Alcohol Abuse. 2012 Mar;38(2):171-5. doi: 10.3109/00952990.2011.643996. Epub 2012 Jan 5.
citation: Jones HE, Tuten M, O'Grady KE. Treating the partners of opioid-dependent pregnant patients: feasibility and efficacy. Am J Drug Alcohol Abuse. 2011 May;37(3):170-8. doi: 10.3109/00952990.2011.563336. Epub 2011 Mar 17.
Clinical trial NCT06276790: Objective Analysis of Caesarean Scar Pregnancy
Official title: The Predictive Value of an Ultrasound Quantitative Scoring System for Treatment Method Selection in Patients With Caesarean Scar Pregnancy: A Single-Centre Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Caesarean Scar Pregnancy
Ultrasound Scoring System
Lead sponsor: Chengde Central Hospital
Sponsor class: OTHER_GOV
First posted: 2024-02-26
Enrollment: 117
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 117 patients with caesarean scar pregnancy admitted to the Obstetrics and Gynecology Inpatient Area of Chengde Central Hospital, China, from January 2019 to December 2022 were selected for this study.

Brief summary: This study uses a systematic scoring method combined with clinical and ultrasound data to comprehensively evaluate patient conditions and explore the guiding value of the ultrasound quantitative scoring system for selecting the surgical approach for caesarean scar pregnancy.


Eligibility criteria: Inclusion Criteria:

* history of at least one previous caesarean section
* symptoms suggestive of caesarean scar pregnancy, such as unexplained abnormal vaginal bleeding, abdominal pain, cervical pain or abnormal uterine activity during pregnancy
* amenorrhea ≤84 days
* ultrasound examination suggesting a single gestational sac with intact morphology
* stable maternal vital signs

Exclusion Criteria:

* mass-type caesarean scar pregnancy
* previous medication or surgical treatment before ultrasound examination
* haemodynamically unstable patients
* patients with surgical contraindications
* incomplete or lost follow-up clinical data
* patients with severe medical conditions such as hypertension, diabetes, hyperthyroidism and haemophilia

Primary outcomes:
measure: intraoperative blood loss
timeFrame: during surgery
measure: length of hospital stay
timeFrame: Within 1 week
measure: serum β-HCG levels
timeFrame: Within 2 weeks after the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Chengde
country: China
facility: Chengde Central Hospital
Study officials:
References:
Clinical trial NCT00509990: Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting
Official title: Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atopic Dermatitis
Keywords: Atopic dermatitis, pimecrolimus, children
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2007-08-01
Enrollment: 200
Sex: ALL
Minimum age (years): 3
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An open-label, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice


Eligibility criteria: Inclusion Criteria:

* Age ≥ 3 months to 12 years old
* Clinical diagnosis of atopic dermatitis
* History of mild to moderate atopic dermatitis
* Investigator Global Assessment ≥ 1 (almost clear/clear of disease)
* Written informed consent

Exclusion Criteria:

* Investigator Global Assessment ≥ 4 (severe/very severe disease)
* Patients with active skin viral infections (i.e, herpes simplex, herpes zoster, varicella)
* Patients with atopic dermatitis, with active clinical infection on area of disease. All active infections must be treated prior to trial inclusion
* Patients in an Immunosuppressive state or with history of malignant disease
* Patients with clinical conditions other that Atopic Dermatitis that according to the investigator may interfere with the evaluation (i.e, Psoriasis, Netherton Syndrome)
* Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: To evaluate the effectiveness of pimecrolimus cream 1% in the long-term management in mild to moderate atopic dermatitis in pediatric patients in a daily practice, as assessed by: • Investigator Global Assessment • Facial Investigator Global Ass
Secondary outcomes:
measure: • To monitor the safety of pimecrolimus cream 1% in the long-term management as assessed by Adverse Events and Serious Adverse Events collection • To evaluate quality of life of both parent and patient assessed by questionnaire. • To determine ste
Other outcomes:
Locations:
city: Mexico
country: Mexico
facility: Novartis Investigative Site
city: Monterrey
country: Mexico
facility: Novartis Investigative Site
city: Puebla
country: Mexico
facility: Novartis Investigative Site
city: Aragua
country: Venezuela
facility: Novartis Investigative Site
city: Carabobo
country: Venezuela
facility: Novartis Investigative Site, Edo
city: Caracas
country: Venezuela
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharma AG, Basel, Switzerland
name: Novartis
role: STUDY_CHAIR
References:
Clinical trial NCT05170490: Long Term Follow up of Chronic HCV Patients Receiving DAAS
Official title: Long Term Follow up of Chronic Hepatitis C Patients Treated With Direct Acting Antivirals After Sustained Virological Response
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Hepatitis c
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-12-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients with chronic hepatitis C who received direct-acting antiviral drugs and scheived SVR

Brief summary: Follow up of Chronic hepatitis C Patients with moderate to severe fibrosis and cirrhosis treated with Direct Acting Antivirals after Sustained Virological Response for 4-5 years to detect changes in hepatic fibrosis and liver functions.

Detailed description: Treatment of chronic hepatitis C is evolving rapidly. Three classes of direct-acting antiviral agents, including inhibitors of the HCV NS3/4A protease, NS5B polymerase, and NS5A have been approved for the treatment of patients with chronic hepatitis C, both in combination with pegylated Interferon (Peg-IFN) / ribavirin (RBV) and, recently, in interferon-free combination.

The objective of chronic hepatitis C treatment is to achieve SVR which is defined as the absence of viral replication at 12 or 24 weeks after treatment completion. SVR reduces morbidity and mortality and is equivalent in most cases to cure the HCV infection. Studies have demonstrated that SVR is associated with histological improvement, assessed by liver biopsy, and with the prevention of complications, such as the development of liver cirrhosis and HCC.

Eligibility criteria: Inclusion Criteria:

* Chronic HCV patients with moderate to severe hepatic fibrosis (F2: F4) or cirrhosis who received direct-acting antivirals and achieved SVR.

Exclusion Criteria:

* Other liver diseases as Chronic hepatitis B and autoimmune liver disease. HIV co-infection.

Primary outcomes:
measure: changes in hepatic fibrosis
timeFrame: 4 years after end of treatment
Secondary outcomes:
measure: change in serum albumin level
timeFrame: 4 years after end of treatment
measure: change in prothrombin level
timeFrame: 4 years after end of treatment
measure: change in bilirubin level
timeFrame: 4 years after end of treatment
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
Clinical trial NCT06716190: A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People
Official title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 3731579 in Healthy Volunteers (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2024-12-04
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.


Eligibility criteria: Inclusion criteria

1. Healthy volunteers according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), respiratory rate (RR) and temperature), 12-lead electrocardiogram (ECG), and clinical laboratory tests
2. Age of 18 to 55 years (inclusive)
3. Body mass index (BMI) of 18.5 to 29.9 kg/m\^2 (inclusive)
4. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial Further inclusion criteria apply.

Exclusion criteria

1. Any finding in the medical examination (including BP, PR, RR, temperature or ECG) deviating from normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or resting pulse rate outside the range of 45 to 90 beats per minute (bpm)
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.

Primary outcomes:
measure: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
timeFrame: up to Day 27.
Secondary outcomes:
measure: AUCτ,ss (area under the concentration-time curve of BI 3731579 in plasma at steady state over a uniform dosing interval τ)
timeFrame: up to Day 19.
measure: Cmax,ss (maximum measured concentration of BI 3731579 in plasma at steady state over a uniform dosing interval τ)
timeFrame: up to Day 19.
Other outcomes:
Locations:
city: Edegem
country: Belgium
facility: SGS Life Science Services - Clinical Research
Study officials:
References:
Clinical trial NCT01218490: Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer
Official title: Pelvic and Aortic-cava Lymphadenectomy Randomized Phase III for Advanced Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE3
Conditions: Ovarian Cancer
Keywords: surgery
ovarian cancer
lymphadectomy
Lead sponsor: Institut Cancerologie de l'Ouest
Sponsor class: OTHER
First posted: 2010-10-11
Enrollment: 450
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: It is a multicenter randomized trial of superior cleaning compared the absence of dissection in stage III patients with optimal surgical resection without retroperitoneal lymph node palpable.


Eligibility criteria: Inclusion Criteria:

* Age\> 18 years
* Karnofsky\> 80, or ASA I-II
* Primary ovarian adenocarcinoma, or primitive peritoneal
* No retroperitoneal lymph node\> 2cm (CT; MRI)
* Complete surgical staging
* Stage III-IV FIGO classification
* Indication of systemic chemotherapy before surgery or post surgery

Exclusion Criteria:

* Non Invasive Cancer
* non-epithelial or borderline cancer
* Pregnancy
* Previous pelvic lymphadenectomy or aortic-cava for a disease other than ovarian cancer
* Contraindication to Platinum and Paclitaxel
* Borderline Ovarian Tumor
* tumor recurrence
* Incomplete surgery, resectable lesion, Surgery sub optimal (R\> 1cm)

Primary outcomes:
measure: survival with out recurrence
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Clinique Sainte Thérèse
city: Angers
country: France
facility: Centre Paul Papin
city: Angers
country: France
facility: Hospital
city: Brest
country: France
facility: Hospital
city: Clermont-Ferrand
country: France
facility: Centre Jean Perrin
city: Dijon
country: France
facility: Centre G F Leclerc
city: Lyon
country: France
facility: Hospital
city: Marseille
country: France
facility: Institut Paoli Calmette
city: Montpellier
country: France
facility: Centre Val d'Aurelle
city: Paris
country: France
facility: Hôpital Européen Georges Pompidou
city: Paris
country: France
facility: Hôpital Lariboisière
city: Paris
country: France
facility: Hôpital des Diaconesses
city: Rennes
country: France
facility: Clinique Mutualiste
city: Rennes
country: France
facility: Hopital
city: Saint Cloud
country: France
facility: Centre René Huguenin
city: Saint Herblain
country: France
facility: Institut Cancerologie de l'Ouest
city: Strasbourg
country: France
facility: Centre Paul Strauss
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Tours
country: France
facility: Hôpital Bretonneau
Study officials:
References:
Clinical trial NCT04975490: Characterization and Pathogenesis of ACLF
Official title: Beobachtungsstudie für Die Charakterisierung Der Pathogenese Des Akut-auf-chronischen Leberversagens
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Cirrhosis
Acute-On-Chronic Liver Failure
Portal Hypertension
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2021-07-23
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with liver cirrhosis and complications

Brief summary: This single-center prospective observational study aims at characterization of pathogenesis of ACLF. There will be three different cohorts investigated with the main endpoint mortality in these groups.

1. SAPIENT = Sepsis ACLF patients, to investigate the differences between ACLF and sepsis in cirrhosis
2. PROACT = Portal mediators as ACLF Targets, to assess portal venous biomarkers in patients receiving TIPS leading to ACLF and identify potential treatment targets
3. ELITE = prEdictors of beneficial LIver Tx in ACFL patiEnts, to assess in ACLF-patients receiving liver transplantation predictors of survival, which may improve selection of ACLF-patients for liver transplantation Secondary endpoints will be different in the three different cohorts and biological material will be collected for separate ancillary studies.


Eligibility criteria: Inclusion Criteria:

* Liver cirrhosis

Exclusion Criteria:

* extrahepatic and metastatic malignancy,
* refusal for participation
* decision of attending phycisian

Primary outcomes:
measure: Mortality
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Translational Hepatology
state: Hessen
Study officials:
affiliation: Goethe University Hospital Frankfurt
name: Jonel Trebicka, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: